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OBJECTIVES The purpose of this study was to determine if therapy with beta-blockade is associated with
reduced cardiomyocyte apoptosis.
BACKGROUND Chronic treatment with beta-adrenergic blocking agents has been shown to improve left
ventricular (LV) ejection fraction and attenuate progressive LV remodeling in heart failure
(HF). Cardiomyocyte apoptosis has also been shown to occur in the failing heart.
METHODS Moderate HF was produced in 14 dogs by intracoronary microembolizations. Dogs were
randomized to three months therapy with metoprolol (MET, 25 mg twice daily, n 5 7) or
to no therapy at all (n 5 7). At the end of three months, dogs were sacrificed, and nuclear
DNA fragmentation (nDNAf), a marker of apoptosis, was assessed in LV tissue using the
TUNEL assay. The number of cardiomyocytes with positive nDNAf labeling per 1,000 was
quantified in LV regions bordering old infarcts and in regions remote from infarcts.
Endonuclease activity and expression of the antiapoptotic protein Bcl-2 and the proapoptotic
proteins Bax and caspase-3 were also evaluated in LV tissue.
RESULTS The number of nDNAf events per 1,000 cardiomyocytes was lower in dogs treated with MET
compared with untreated dogs with HF in the border regions (0.35 6 0.07 vs. 5.32 6 0.77,
p , 0.001) as well as the remote regions (0.07 6 0.05 vs. 0.39 6 0.12, p , 0.05).
Endonuclease activity was also significantly lower in MET-treated compared with untreated
dogs (25 6 3 vs. 37 6 2 ng [3H]DNA rendered soluble/min/mg protein). Western blotting
for Bcl-2, Bax and caspase-3 showed increased expression of Bcl-2, decreased expression of
caspase-3 and no change in Bax in MET-treated compared with untreated dogs.
CONCLUSIONS Chronic therapy with MET attenuates cardiomyocyte apoptosis in dogs with moderate HF.
Attenuation of ongoing cardiomyocyte loss through apoptosis may be one mechanism
through which beta-blockers elicit their benefits in HF. (J Am Coll Cardiol 2000;36:
1698–705) © 2000 by the American College of Cardiology
Chronic therapy with beta-adrenergic blocking agents in
heart failure (HF) is associated with improved global left
ventricular (LV) function and chamber remodeling (1–3).
In dogs with moderate HF produced by intracoronary
microembolizations, we showed that chronic therapy with
metoprolol (MET) improves LV ejection fraction and
attenuates progressive LV chamber dilation (4). An under-
standing of the mechanisms that mediate these beneficial
effects of beta-blockers in HF remains elusive. A possible
hypothesis is that progressive deterioration of LV function
in HF is mediated, in part, by ongoing loss of cardiomyo-
cytes and that therapy with beta-blockers has a positive
impact on this process. Studies in dogs with HF (5) and in
explanted failed human hearts (6) have documented the
occurrence of cardiomyocyte apoptosis, a process that may
account, in part, for the loss of cardiomyocytes (5). Apo-
ptosis is an active, energy requiring, genetically-controlled
process that is characterized by nuclear DNA fragmentation
(nDNAf) (7). Biochemically, apoptosis is characterized by
internucleosomal cleavage of DNA by endonucleases whose
activity increases during apoptosis (8). Recent studies have
suggested that factors inherent to HF, including
angiotensin-II (9), norepinephrine (10) and tissue hypoxia
(11) can stimulate cardiomyocyte apoptosis. In this study,
we tested the hypothesis that the benefits of chronic
treatment with the beta-blocker MET in dogs with mod-
erate HF may be mediated, in part, by attenuation of
cardiomyocyte apoptosis. In addition to quantifying the
number of nDNAf events, the effects of MET on endoge-
nous endonuclease activity, a key surrogate of ongoing
internucleosomal DNA cleavage, was also evaluated. The
expression of Bcl-2, Bax and caspase-3 in the LV myocar-
dium was also examined because of the recognized proapop-
totic effects of Bax and caspase-3 and the antiapoptotic
effect of Bcl-2.
METHODS
Animal model and study protocol. The canine model of
chronic HF used in this study was previously described in
detail (12). In this model, chronic LV dysfunction is
produced by multiple sequential intracoronary emboliza-
tions with polystyrene latex microspheres (77 to 102 mm
diameter). A unique feature of this model is the progressive
deterioration of LV function that occurs long after cessation
of coronary microembolizations (4,12). In this study, 14
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dogs weighing between 21 and 34 kg underwent coronary
microembolizations to produce HF (4). The cohort of dogs
used represents a subset of a previously published larger
study in which three months therapy with MET was shown
to improve LV ejection fraction and attenuate progressive
LV chamber dilation (4). The detailed methods of emboli-
zation, anesthesia and hemodynamic assessment were re-
ported as part of the larger study (4). Three weeks after a
target LV ejection fraction of 30% to 40% was reached,
embolizations were discontinued, and dogs were random-
ized to three months oral monotherapy with MET (25 mg
twice daily, n 5 7) or no therapy at all (n 5 7). Hearts were
harvested at the end of three months of or active therapy.
Hearts from 6 normal dogs were also harvested and used for
comparisons. The study was approved by the Henry Ford
Hospital Care of Experimental Animals Committee and
conformed to the position of the American Heart Associ-
ation on research animal use.
Identification of nuclear DNA fragmentation. At the
end of three months of therapy, the dog’s chest was opened
and the heart rapidly removed and placed in ice-cold
cardioplegia solution. From each heart, transverse slices (3
to 4 mm thick) were obtained from the LV midventricular
level and cut into several blocks, each labeled for anatomical
location. Transmural blocks were fixed in formalin and
embedded in paraffin. Sections 5 mm thick were prepared,
deparaffinized in xylene and rehydrated through graded
ethanol washes. Sections were then fixed in freshly prepared
4% paraformaldehyde and treated with 10 mg/ml proteinase
K and triple stained as shown in Figure 1, A to C. Sections
were first stained using the Apoptosis Fluorescein Detection
System (Promega Corp., Madison, Wisconsin) to identify
cells showing nDNAf. In this process, fluorescein-12-
deoxyuridine 59-triphosphate (dUTP) is catalytically incor-
porated at the 39-OH fragmented DNA ends of apoptotic
cells using the terminal deoxynucleotidal transferase (TdT)
enzyme, which forms a polymeric tail as in the TUNEL
(TdT-mediated dUTP nick-end labeling) assay. Negative
control studies, namely, tissue sections processed for
TUNEL without TdT were performed for each dog. To
identify cardiomyocytes, sections were stained overnight at
4°C with a monoclonal ventricular heavy chain antimyosin
antibody (Chemicon, Temecula, California). For visualiza-
tion, a rhodamine conjugated secondary antimouse antibody
was used. Lastly, to identify nuclei, sections were stained
using the specific nuclear stain, Hoechst 33342 (Molecular
Probes, Inc., Eugene, Oregon). Using the above sequence of
staining, nDNAf events were visualized microscopically as
yellow-green under fluorescein light (Nikon DM510 filter;
Tokyo, Japan); myosin was seen as red under rhodamine
light (Nikon DM 580 filter), and cell nuclei were seen as
blue (Nikon DM 455 filter). From each section, 80 light
microscopic fields (magnification 340) were used to count
Abbreviations and Acronyms
CSQ 5 calsequestrin
HF 5 heart failure
LV 5 left ventricular
MET 5 metoprolol
nDNAf 5 nuclear DNA fragmentation
SDS 5 sodium dodecyl sulfate
TdT 5 terminal deoxynucleotidal transferase
TUNEL 5 TdT-mediated dUTP nick-end labeling
Figure 1. Panels A, B and C: Section of left ventricular myocardium
showing cardiomyocytes bordering scar tissue from an untreated dog with
heart failure (magnification 3 750). (A) Shows a cardiomyocyte positively
stained (red) with antimyosin antibody, identifying the cell as a cardiomy-
ocyte. The unstained center region is the nucleus. (B) Shows the same
cardiomyocyte nucleus stained positively (blue) with the specific nuclear
stain Hoechst 33342. (C) Shows the same left ventricular section as in (A)
and (B). The nucleus is positively stained (yellow-green) for nuclear DNA
fragmentation.
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the number cardiomyocyte nuclei positively labeled for
nDNAf. Forty fields were selected at random from myocar-
dial regions bordering scar tissue (old infarcts) and 40 fields
from myocardial regions remote from scars. The selection of
regions bordering scars was made due to the high incidence
of cardiomyocyte apoptosis previously identified in these
regions (5). The number of cardiomyocytes positively la-
beled for nDNAf was counted in each field. The number of
cardiomyocytes per field was determined by counting an
average of 40 fields in each ventricular sample. By combin-
ing these data with the estimated numbers of positively
dUTP-labeled cardiomyocytes, the number of nDNAf
events per 1,000 cardiomyocytes was determined (6). In
tissue sections stained with antimyosin antibody, a scar or
infarct was defined as a myocardial region devoid of myo-
cytes and occupying a surface area equivalent to that of at
least 1,000 myocytes, as visualized at a magnification of 103
and as previously described (13). Confirmation that these
regions indeed represented scar tissue was made by immu-
nostaining sections with antibodies for collagens I and III.
The region bordering a scar or infarct was defined using
antimyosin stained sections as a peri-infarct region consist-
ing of 10 rows of myocytes adjacent to the scar counted
radially starting at the scar to viable tissue interface. A
remote myocardial region was defined as any area that was
at least 100 myocytes away from any infarct in all directions.
These definitions, while empirical, are consistent with
previous work from our laboratory (13,14).
Assessment of endonuclease activity. Endonuclease activ-
ity was determined as previously described (8) with minor
modifications using tissue obtained from six normal dogs,
six untreated dogs with HF and six dogs with HF treated
with MET. From each dog, approximately 100 mg of
frozen LV powder was homogenized in 1 ml of freshly
prepared and ice-chilled buffer A (50 mM Tris-HCl, pH
7.4, 0.5 mM EDTA, 0.5 mM EGTA, 0.3 mM sucrose,
50 mM sucrose, 2 mM benzamidine, 1 mg/ml aprotinin and
2 mg/ml leupeptin). The resulting homogenate was filtered,
aliquoted, rapidly frozen in liquid nitrogen and immediately
stored at 270°C. The enzyme activity assay was performed
in a total assay volume of 100 ml reaction volume that
consisted of 50 mM Tris-HCl, pH 7.4, 5 mM MgCl2, 5 mg
Escherichia coli DNA ([3H]DNA 5 20,000 dpm) and 50 mg
LV homogenate. The reaction was initiated by adding the
homogenate and terminated after incubating at 37°C for 1 h
by adding 20 ml of 14% perchloric acid followed by 20 ml of
25 mg/ml bovine serum albumin. The resulting mixture was
vortexed, centrifuged at 12,000 rpm for 5 min, and an
aliquot of 100 ml of the clear supernatant was counted for
radioactivity in the presence of 5 ml of scintillation fluid
using a scintillation counter. Endonuclease activity was
expressed as ng [3H]DNA rendered soluble/min/mg pro-
tein.
Western blotting for Bcl-2, Bax and caspase-3. Tissue
levels of Bcl-2, Bax and caspase-3 in LV myocardium were
examined using Western blotting. Protein levels were de-
termined in tissue sodium dodecyl sulfate (SDS) extract.
Expression of Bax and caspase-3 was assessed in six un-
treated dogs with HF and six dogs treated with MET. Bcl-2
expression was assessed in five dogs from each of the two
study groups. To determine whether differences in tissue
levels of Bax, Bcl-2 and caspase-3 exist between normal
dogs and untreated dogs with HF, LV tissue from six
normal dogs was used, and the results were compared with
untreated dogs with HF. In addition, tissue levels of
calsequestrin (CSQ), a sarcoplasmic reticulum protein, was
also examined in all normal dogs, in untreated dogs with
HF and in MET-treated dogs. Calsequestrin does not
change in HF and, as such, was used as an internal control
(15). The SDS-extract of approximately 25 mg of tissue
powder was prepared from the LV free wall of each dog as
previously described (16). Equal volumes of the SDS-
extract and sample buffer (62.5 mM Tris-HCl, pH 6.8; 20%
glycerol and 40 mM DTT with 0.001% bromophenol blue)
were combined, and the resulting mixture was incubated in
a boiling water bath for 10 min. An aliquot of the boiled
mixture, corresponding to 30 mg for Bcl-2 and caspase-3, or
10 mg for Bax and CSQ, was separated on 12% SDS-
polyacrylamide gel, and the separated proteins were then
transferred to nitrocellulose as previously described (16). To
determine Bcl-2 and caspase-3 tissue levels, samples from
normal dogs, untreated dogs with HF and MET-treated
dogs were incubated with a 500-fold diluted monoclonal
mouse anti-Bcl-2 or anti-caspase-3 antibody (Transduction
Laboratory, Lexington, Kentucky). For determination of
Bax tissue levels, samples were incubated with a 200-fold
diluted rabbit polyclonal antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, California). For determination of CSQ
tissue levels, samples were incubated with 250-fold diluted
polyclonal rabbit skeletal muscle antibody raised against
CSQ purified from canine ventricular sarcoplasmic reticu-
lum. Monoclonal antibody binding protein was visualized
calorimetrically using either antimouse IgG raised in sheep
and polyclonal antibody binding protein, using antirabbit
IgG raised in donkey. The intensity of the bands was
quantified using a Bio-Rad Model GS-670 imaging densi-
tometer. The densitometric unit of measurement used was
optical density 3 mm2.
Data analysis. Repeated-measures analysis of variance was
used to examine the nDNAf outcomes to take into account
the two regions (border zone and remote zone) that were
examined. For endonuclease activity and CSQ one-way
analysis of variance was performed. For other outcomes,
namely Bax, Bcl-2 and caspase-3, Western blots were
performed at different times for MET-treated versus un-
treated dogs with HF and for untreated dogs with HF
versus normal dogs. Since the band density measurements
for separate runs are not directly comparable due to different
exposure times, two separate t tests were performed. In all
instances, the Hochberg-Holms (17) modification of the
Bonferroni adjustment was used to account for multiple
comparisons. In the Hochberg-Holms method, if the larg-
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est of two or three p values is less than 0.05, then all the tests
with smaller p values are considered significant. Only p
values meeting this criterion are reported as significant. All
data are reported as the mean 6 standard error of the mean.
RESULTS
Effect of treatment with MET on nDNAf. In dogs with
HF, regardless of treatment, nDNAf was identified in
cardiomyocytes remote from any scars as well as in constit-
uent cardiomyocytes of regions bordering scars. On statis-
tical grounds, there was a significant interaction between
regions and MET effect for nDNAf (p , 0.001). Therefore,
separate tests of the MET effect were made for each region,
namely border zone and remote zone. Regardless of therapy,
the number of nDNAf events of cardiomyocyte origin was
always higher in LV regions bordering scars compared with
LV regions remote from any scars (Table 1). A typical
high-powered micrograph depicting nDNAf in a cardiomy-
ocyte is shown in Figure 1. There was a significantly lower
incidence of nDNAf events of cardiomyocyte origin in
regions bordering old infarcts of MET-treated compared
with untreated dogs with HF. Similarly, there was a
significantly lower incidence of cardiomyocyte nDNAf
events in LV regions remote from infarcts of dogs that were
MET-treated compared with untreated dogs with HF
(Table 1).
Effect of treatment with MET on endonuclease activity.
Tissue endonuclease activity was significantly higher in
untreated dogs with HF compared with normal dogs (36 6
2 vs. 23 6 2 ng[3H]DNA rendered soluble/min/mg pro-
tein, p , 0.001). Consistent with findings of a reduced
number of nDNAf events with MET, endonuclease activity
was significantly lower in MET-treated compared with
untreated dogs with HF (25 6 2 vs. 36 6 2 ng[3H]DNA
rendered soluble/min/mg protein, p , 0.01). There was no
significant difference in endonuclease activity between nor-
mal and MET-treated dogs (Fig. 2).
Expression of CSQ, Bax, Bcl-2 and caspase-3. Figure 3
depicts expression of CSQ in three normal dogs, three
untreated dogs with HF and three MET-treated dogs.
There was no difference in the expression of CSQ among six
normal dogs, six untreated dogs with HF and six MET-
treated dogs (12.0 6 1.1 vs. 11.1 6 1.0 vs. 11.4 6 1.0
densitometric U). Figure 4 shows a Western blot depicting
the expression of Bax in three normal dogs and three
untreated dogs with HF. Densitometric analysis of Western
blots showed no differences in the expression of Bax
between six normal dogs and six untreated dogs with HF
(2.4 6 0.2 vs. 2.3 6 0.1 densitometric U). Figure 4 depicts
expression of Bax in three untreated dogs with HF and three
MET-treated dogs. Densitometric analysis of Western
blots showed no differences in the expression of Bax
between six untreated dogs with HF and six MET-treated
dogs (6.2 6 0.6 vs. 5.6 6 0.7 densitometric U).
Figure 5 depicts expression of Bcl-2 in three normal and
three untreated dogs with HF. Expression of Bcl-2 was
increased in untreated dogs with HF compared with normal
dogs. Densitometric analysis of Western blots showed an
increase in the expression of Bcl-2 in six untreated dogs with
HF compared with six normal dogs (8.2 6 0.1 vs. 2.5 6 0.2
densitometric U, p , 0.001). Figure 5 also shows expression
of Bcl-2 in five untreated dogs with HF and five MET-
treated dogs. Upregulation of Bcl-2 is evident in MET-
treated compared with untreated dogs with HF. Densito-
metric analysis of Western blot showed a significant increase
in the expression of Bcl-2 in MET-treated compared with
untreated dogs with HF (17.5 6 1.2 vs. 9.9 6 1.3
densitometric U).
Figure 6 shows expression of caspase-3 in three normal
and three untreated dogs with HF. Caspase-3 was clearly
over-expressed in untreated dogs with HF compared with
normal dogs. Densitometric analysis of Western blots
showed an increase in the expression of caspase-3 in six
untreated dogs with HF compared with normal dogs (2.5 6
Table 1. Number of nDNAf per 1,000 Cardiomyocytes in
Untreated Dogs With HF and Dogs with HF Treated
With Metoprolol
Number of nDNAf per 1,000 Cardiomyocytes
HF Untreated
(n 5 7)
HF-MET
(n 5 7) p Value
Border zone 5.32 6 0.77 0.39 6 0.12 , 0.001
Remote zone 0.39 6 0.12* 0.07 6 0.05* , 0.05
Data are shown for left ventricular regions bordering old infarcts (Border) and regions
remote from any infarcts (Remote).
P value 5 HF-control vs. HF-MET; *p , 0.001 border zone vs. remote zone.
nDNAf 5 nuclear DNA fragmentation events; HF 5 heart failure; HF-MET 5
heart failure treated with metoprolol.
Figure 2. Bar graph (mean 6 SEM) depicting endonuclease activity
measured in left ventricular tissue homogenate prepared from six normal
dogs (NL), six dogs with heart failure that were untreated (HF) and six
dogs with HF treated with metoprolol (HF-MET).
Figure 3. Western blot depicting the expression of calsequestrin (CSQ) in
three normal (NL) dogs, three dogs with heart failure (HF) that were
untreated and three dogs with HF treated with metoprolol (HF-MET).
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0.2 vs. 0.3 6 0.1 densitometric U, p , 0.001). Figure 6 also
shows a Western blot of the expression of caspase-3 in three
untreated dogs with HF and three MET-treated dogs.
Downregulation of caspase-3 is evident in MET-treated
dogs compared with untreated dogs with HF. Densitomet-
ric analysis of Western blots from all six untreated dogs with
HF and six MET-treated dogs showed a significant de-
crease in the expression of caspase-3 in dogs treated with
MET (7.5 6 0.8 vs. 24.9 6 2.8 densitometric U) (p ,
0.001).
DISCUSSION
The results indicate that chronic therapy with the beta1-
adrenergic receptor blocker, MET, attenuates cardiomyo-
cyte apoptosis in LV myocardium of dogs with HF. In
MET-treated dogs the incidence of cardiomyocyte apopto-
sis was lower in both LV regions bordering old infarcts and
in regions remote from any infarcts. The higher incidence of
cardiomyocyte apoptosis in peri-infarct regions is consistent
with previous reports in both animals and patients with HF
and may be due to the susceptibility of these regions to
hypoxia or ischemia, both of which are potential triggers for
apoptosis (18). The overall incidence of cardiomyocyte
apoptosis was approximately 2.9 cardiomyocytes per 1,000,
which is consistent with findings in failed human hearts,
whereby an incidence of 2.4 cardiomyocytes per 1,000 was
reported (6). The observations are also consistent with
findings by Yue et al. (19) who demonstrated a reduction in
cardiomyocyte apoptosis in a rabbit model of myocardial
ischemia/reperfusion after treatment with the nonselective
beta-blocker, carvedilol. The observation of a reduced inci-
dence of TUNEL-positive cardiomyocytes in MET-treated
dogs is in line with the finding of reduced LV tissue levels
of endonuclease activity. The latter is a family of enzymes
responsible for internucleosomal cleavage of DNA and
whose activity increases during apoptosis (8). Our findings
of increased endonuclease activity in the LV tissue of dogs
with HF that were untreated is also consistent with findings
of Yao et al. (20), who showed that deoxyribonuclease I,
which is indistinguishable from endonuclease, is signifi-
cantly increased in the myocardium of patients with end-
stage HF compared with the myocardium of nondiseased
human hearts.
Angiotensin-II, norepinephrine and cardiomyocyte
apoptosis. It has become abundantly clear in recent years
that interference with the renin-angiotensin system in the
form of angiotensin-converting enzyme inhibition as well as
interference with the sympathetic nervous system in the
form of beta-blockade in HF can positively impact LV
function and remodeling. The mechanisms responsible for
the beneficial effects of these agents in HF are not fully
understood. Exposure of cultured adult rat cardiomyocytes
Figure 4. Top: Western blot depicting the expression of Bax in three
normal (NL) dogs and three untreated dogs with heart failure (HF).
Bottom: Western blot depicting the expression of Bax in three dogs with
HF that were untreated and three dogs with HF treated with metoprolol
(HF-MET). Western blots were performed at different times for MET-
treated versus untreated dogs with HF and for untreated dogs with HF
versus NL dogs and, therefore, while directionally consistent, the band
density measurements are not directly comparable due to different exposure
times.
Figure 5. Top: Western blot depicting the expression of Bcl-2 in three
normal (NL) dogs and three untreated dogs with heart failure (HF).
Bottom: Western blot depicting the expression of Bcl-2 in five dogs with
heart failure that were untreated (HF) and five dogs with HF that were
treated with metoprolol (HF-MET). Western blots were performed at
different times for MET-treated versus untreated dogs with HF and for
untreated dogs with HF versus NL dogs and, therefore, while directionally
consistent, the band density measurements are not directly comparable due
to different exposure times.
Figure 6. Top: Western blot depicting the expression of caspase-3 in three
normal (NL) dogs and three untreated dogs with heart failure (HF).
Bottom: Western blot depicting the expression of caspase-3 in three dogs
with HF that were untreated (HF) and three dogs with HF that were
treated with metoprolol (HF-MET). Western blots were performed at
different times for MET-treated versus untreated dogs with HF and for
untreated dogs with HF versus NL dogs and, therefore, while directionally
consistent, the band density measurements are not directly comparable due
to different exposure times.
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to angiotensin-II induced apoptosis that was blocked by
treatment with the AT1-receptor antagonist, losartan (9).
Angiotensin-II can also stimulate the release of norepineph-
rine from nerve terminals. Enhanced and sustained activity
of the sympathetic nervous system is a central feature of HF.
Exposure to high levels of catecholamines has long been
postulated to be toxic to cardiomyocytes. Mann and col-
leagues (21) showed that norepinephrine exerts a direct
toxic effect on cardiac myocytes in vitro and showed that
this effect was mediated by beta-adrenergic receptor stimu-
lation and associated with increased cyclic adenosine mono-
phosphate and calcium influx. This concept was supported
by the results of a recent study that showed that exposure of
adult rat cardiomyocytes to norepinephrine leads to apopto-
sis through activation of the beta-adrenergic receptor path-
way (10). Observations made in this study are in agreement
with recent reports indicating that norepinephrine-
mediated apoptosis occurs via a beta1-adrenergic receptor
pathway (22).
Effects of beta-blockade on Bcl-2 and caspases. In this
study, we observed an upregulation in the expression of
Bcl-2 in untreated dogs with HF compared with normal
dogs; in our observation there was no increase in Bax. We
also observed further upregulation in the expression of the
Bcl-2 in MET-treated dogs compared with untreated dogs
with HF; we observed no associated increase in Bax. The
increase in Bcl-2 seen in untreated dogs with HF and in
MET-treated dogs may have limited the formation of Bax
homodimers (23). These data suggest the possibility that
MET induces the expression of Bcl-2 independent of HF
and that this independently confers protection. The means
by which beta-blockade elicits upregulation of Bcl-2 in the
setting of HF is not known. Alterations in Bcl-2 have been
shown to modulate apoptosis in at least three ways. First,
Bcl-2 has been shown to prevent hypoxia-induced apoptosis
(24). In this study the highest incidence of cardiomyocyte
apoptosis occurred in regions bordering old infarcts that are
susceptible to hypoxia/ischemia (25). Beta-blockers reduce
myocardial oxygen consumption secondary to afterload and
preload reduction as well as reductions of heart rate and wall
stress (4), which, in turn, can increase the threshold for
apoptosis. Second, Bcl-2 regulates an antioxidant pathway
at sites of free radical generation (26) such that an increase
in Bcl-2 may be crucial in preventing programmed cell
death. Third, Bcl-2 may also be directly involved in the
mechanism of calcium-induced cell death as alluded to
earlier. It has recently been shown that the calcium-
activated protein phosphatase, calcineurine, can bind to
Bcl-2, preventing its translocation into the nucleus. Since
calcineurine has been implicated in calcium-mediated apo-
ptotic cell death, its association with Bcl-2 may be relevant
to cell loss in the setting of elevated cytosolic calcium
conditions such as in HF (27).
Another factor involved in the regulation of apoptosis is
the interleukin-converting enzyme family of cysteine pro-
teases, also known as caspases. Recent studies have sug-
gested that caspases can mediate apoptosis in cultured
cardiomyocytes based on the ability of certain caspase
inhibitors, such as zVAD-fmk, to block the apoptotic
process (28). In this study the development of HF was
associated with increased expression of caspase-3 (CPP-32),
while treatment with MET was associated with decreased
expression of caspase-3. Again, the exact mechanism by
which MET mediates reduced expression of caspase-3 is
not known. In a recent study, Black and colleagues (29)
showed colocalization of caspase-3 with apoptotic cardio-
myocytes after myocardial ischemia/reperfusion in the rat.
Other studies have also suggested a close association be-
tween Bcl-2 and activation of caspase cascade, with the
latter prevented by upregulation of Bcl-2 (30). Results of
our study are consistent with these suggestions in that the
observed increase in the expression of Bcl-2 in MET-
treated dogs was associated with reduced expression of
caspase-3.
Effects of beta-blockade on other mediators of apoptosis.
The above rationale conferring an antiapoptotic function to
beta-blockers through stimulation of Bcl-2 expression and
caspase-3 inhibition is only one possible mechanism by
which beta-blockade can act to preserve cardiomyocytes in
the setting of HF. Another possible action, alluded to
earlier, may be mediated by reduction of circulating levels of
norepinephrine (10). Enhanced norepinephrine release can
mediate apoptosis through activation of protein kinase A,
leading to increased calcium entry via voltage-dependent
calcium channels (10). While not examined in this study, it
is also possible that newer, so-called third generation
beta-blockers can attenuate cardiomyocyte apoptosis by
downregulation of the stress-activated protein kinase sig-
naling pathway or by inhibiting Fas receptor expression
(19). Finally, it is by no means certain that the modulation
of cardiomyocyte apoptosis seen in this study is unique to
beta-blockers and to interference with the sympathoadren-
ergic activation. We previously reported attenuation of
cardiomyocyte apoptosis in peri-infarct regions in dogs with
HF treated with an angiotensin-converting enzyme inhib-
itor. The fact that both classes of drugs appear to limit
cardiomyocyte apoptosis in HF argues in favor of multiple
pathways to the prevention of programmed cell death in the
failing heart.
Study limitations. This study is not without limitations.
Identification of nuclear DNA breaks using the TUNEL
assay was used to quantify cardiomyocyte apoptosis. Some
studies have suggested that internucleosomal DNA cleavage
can occur in both apoptosis and necrosis (31). Other studies,
however, have shown that the intensity of the dUTP
labeling when a cell is undergoing apoptosis is as much as
20-fold higher than when the same type of cell undergoes
necrosis (32). Thus, when both apoptosis and necrosis are
present, the very low intensity labeling of necrotic cells
makes identification very difficult, if not impossible. Fur-
thermore, in this investigation, cardiomyocyte nDNAf was
examined in dogs with HF studied three months after the
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last microembolization when all infarcts were healed. In
several studies in which this canine model was used, we were
not able to identify cardiomyocyte necrosis in the late
chronic stage of HF, namely long after (3 to 4 months)
completion of intracoronary microembolizations (4,5,12–
14). Another limitation to the use of the TUNEL method
to quantify the absolute number of cardiomyocytes under-
going apoptosis is that not all cardiomyocytes have their
nuclei in the plain of the histologic section and, for this
reason, cannot be judged as undergoing apoptosis or not.
This limitation is minimized, however, when comparisons
are performed among study groups, as in this work, using
identical histologic techniques. Furthermore, the directional
changes observed using the TUNEL method are in line
with changes in endonuclease activity, a marker of apopto-
sis. In this study, the pro form of caspase-3, and not the
active form, was measured. It is possible, therefore, that the
decrease of pro-caspase-3 observed in dogs treated with
MET is secondary to cleavage of pro-caspase-3 to generate
active caspase-3; the latter was not measured in this study.
This possibility is not a likely explanation for our observa-
tion. An increase in active caspase-3 in MET-treated dogs
would not be consistent with the marked reduction in
TUNEL-positive cardiomyocytes, a significant decrease in
endonuclease activity and a significant increase in Bcl-2 in
dogs with HF treated with MET compared with untreated
dogs with HF. Finally, the study design, one time point at
the end of three months of therapy, did not allow for
determination of the rate at which apoptosis occurs during
the progressive phase of the disease, and, therefore, no firm
implications can be derived at this time with regard to the
role of beta-blockade in modulating cardiomyocyte apopto-
sis during the course of progressive LV dysfunction.
Conclusions. The observations made in this study indicate
that chronic treatment with the beta-blocker, MET, in dogs
with moderate HF attenuates cardiomyocyte apoptosis. The
attenuation of cardiomyocyte apoptosis with MET therapy
is associated with a reduction in endonuclease activity, an
increase in Bcl-2 expression and a reduction of caspase-3
without changes in Bax—all of which favor cell survival.
Preventing or attenuating ongoing loss of functional cardiac
units in HF by apoptosis may be one mechanism by which
beta-blockers preserve LV function and chamber remodel-
ing in the failing heart.
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